The effect of dietary fat load on the size and composition of chylomicrons
in thoracic duct lymph.
5] Nonstandard abbreviations: T2DM, type 2 diabetes mellitus; TC, total cholesterol; LDL-C, LDL cholesterol; apo B, apolipoprotein B; HBL, hypobetalipoproteinemia; ABL, abetalipoproteinemia; CMRD, chylomicron
retention disease; FHBL, familial HBL; MGUS, monoclonal gammopathy of undetermined significance.
LPL deficiency causes massive accumulation of chylomicrons
Cholesterol is transported in plasma mainly by low-density lipoproteins (LDL) and chylomicron
A specific measurement of chylomicrons
and a large VLDL might explain the time effect.
This publication provides additional, independent support on the ability of Glybera to restore chylomicron
metabolism in LPLD patients.
Omega-3 fatty acid supplementation accelerates chylomicron
This results in the accumulation of lipid droplets in the intestine and the liver, due to an inability to produce chylomicrons
and VLDL in the intestine and liver, respectively.
The main compositional difference between VLDL remnants and chylomicron
remnants is the presence of apo B 100 as the major protein of VLDL remnants, rather than apo B48, and the lower relative triglyceride concentration.
now validated as biomarker for Glybera efficacy; data presented at American Society of Gene and Cell Therapy annual meeting
Plasma clearance and liver uptake of chylomicron
remnants generated by hepatic lipase lipolysis: evidence for a lactoferrin-sensitive and apolipoprotein E-independent pathway.
From what we know today, despite the disappointment, we believe that there is an indication from the CHMP that Glybera could receive approval and that the current opinion at this time is a reflection of insufficient proof of clinical benefit of Glybera as a result of low patient numbers measured for chylomicron
handling for at least 12 months post treatment.
Postprandial lipids and their associated partially hydrolyzed chylomicron
remnants appear to promote early atherogenesis, adversely affect endothelial function, associate with atherogenic small LDL particles, and correlate with both prothrombotic and proinflammatory biomarkers, including factor VII, plasminogen activator inhibitor-1, and C-reactive protein (4).
AMSTERDAM, May 20, 2011 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron
metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.
Later this month we will present additional data at ASGCT regarding improved chylomicron
handling, which we believe could be used in the future by physicians as a biomarker for Glybera in LPLD patients.